Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution.
OBJECTIVE
To determine the effects of gender, race, and fat redistribution on growth hormone (GH) secretory patterns in HIV-infected patients.


METHODS
We investigated GH responses to growth hormone releasing hormone (GHRH) + arginine stimulation testing in HIV-infected subjects with fat redistribution, comparing HIV-infected males (n = 139) and females (n = 25) to non HIV-infected male (n = 25) and female (n = 26) control subjects similar in age, body mass index and race.


METHODS
A standard GHRH + arginine stimulation test [GHRH 1 microg/kg and arginine 0.5 g/kg (maximum dose 30 g)] was performed, and fat redistribution was assessed by anthropometry.


RESULTS
HIV-infected women had significantly higher peak GH in response to GHRH + arginine (36.4 +/- 7.3 versus 18.9 +/- 2.0 ng/ml; P = 0.003) and GH area under curve (AUC) (2679 +/- 593 versus 1284 +/- 133 (mg-min)/dl, P < 0.001) compared to HIV-infected men. Among men, a cutoff of 7.5 ng/ml for peak GH response on the GHRH + arginine test achieved good specificity and sensitivity and optimally separated the HIV and control groups (e.g., the failure rates were 37% versus 8%; P = 0.004, respectively). Among women, no specific cutoff could be determined to separate the HIV-infected and control subjects. Non-Caucasians demonstrated a higher GH AUC response compared to Caucasians, among the HIV-infected male subjects. In stepwise regression modeling waist-to-hip ratio was most significantly related to peak GH in response to GHRH + arginine in HIV-infected men.


CONCLUSIONS
HIV-infected men with fat redistribution have significantly reduced GH peak responses and increased failure rates to standardized GH stimulation testing in comparison to healthy male control subjects and to HIV-infected women of similar age and body mass index. GH secretion is related to gender and race in HIV-infected patients.
Massachusetts General Hospital Program in Nutritional Metabolism and Neuroendocrine Unit, Harvard Medical School, Boston, Massachusetts 02114, USA.
Polyxeni
P
Koutkia
Kristina
K
Eaton
Sung Min
SM
You
Jeff
J
Breu
Steven
S
Grinspoon
D000273:Adipose Tissue / Q000473:pathology*; D000328:Adult; D000886:Anthropometry; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001120:Arginine; D015992:Body Mass Index; D018791:CD4 Lymphocyte Count; D005260:Female; D013007:Growth Hormone-Releasing Hormone; D015658:HIV Infections / Q000188:drug therapy / Q000208:ethnology / Q000378:metabolism* / Q000473:pathology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000208:ethnology / Q000378:metabolism / Q000473:pathology; D019382:Human Growth Hormone / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D008297:Male; D008598:Menstruation; D008875:Middle Aged; D012737:Sex Factors; D019562:Viral Load; D049629:Waist-Hip Ratio
D019380:Anti-HIV Agents; D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine